# Efficacy and Safety of Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes in the Treatment of Diabetic Foot Ulcers: A Double-blinded Randomized Controlled Clinical Trial

> **NCT06812637** · PHASE1 · COMPLETED · sponsor: **Kafrelsheikh University** · enrollment: 110 (actual)

## Conditions studied

- Diabetic Foot Ulcer (DFU)
- Exosomes

## Interventions

- **DRUG:** WJ-MSC- Exosomes
- **COMBINATION_PRODUCT:** SOC (Standard of care)
- **OTHER:** Vehicle (placebo)

## Key facts

- **NCT ID:** NCT06812637
- **Lead sponsor:** Kafrelsheikh University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-06
- **Primary completion:** 2024-06-06
- **Final completion:** 2024-09-02
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06812637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06812637, "Efficacy and Safety of Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes in the Treatment of Diabetic Foot Ulcers: A Double-blinded Randomized Controlled Clinical Trial". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT06812637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*